丙型肝炎病毒感染与治疗药物

戚中田

丙型肝炎病毒感染与治疗药物

戚中田

第二军医大学微生物教研室

基金项目:

国家传染病重大专项课题(2008ZX10002-013)；国家新药创制重大专项课题(2008ZXJ09009-002)；上海市重点学科建设项目(B901)；

详细信息

中图分类号: R512.63
计量
- 文章访问数: 4589
- HTML全文浏览量: 19
- PDF下载量: 1606
- 被引次数: 0
出版历程
- 出版日期: 2011-01-20

Hepatitis C virus infection and its therapeutic drugs

Qi ZhongTian

Research funding:

摘要

摘要:
丙型肝炎病毒（HCV）通过在宿主细胞内持续复制,导致慢性感染。目前用于治疗慢性丙型肝炎（CHC）的药物主要是聚乙二醇干扰素（PEG-IFN）和利巴韦林的联合用药。本文将就HCV的细胞入侵、复制、逃避宿主的固有和获得性免疫,以及抗HCV临床试验药物的最新进展做一综述。
- 肝炎,丙型 /
- 肝炎病毒属
Abstract:
Hepatitis C virus (HCV) can lead to chronic hepatitis C (CHC) in ways that favor viral replication and persistent infection.The current standard treatment for hepatitis C virus infection is the combination of pegylated IFN with ribavirin (PEG-IFN/RBV) .In the recent years there has been significant advances in the understanding of viral replication and the development of anti-virus agents.This review summarizes the current knowledge of HCV cell entry, replication, escaping host innate and adaptive immune responses and current clinical trails of anti-HCV drugs.
- hepatitis C /
- hepacivirus

HTML全文

参考文献(25)

[1]Nakano T, Lu L, He Y, et al.Population genetic history of hepatitis C virus 1b infection in China[J].J Gen Virol, 2006, 87 (Pt 1) :73-82.

[2]Kemmer N, Neff GW.Managing chronic hepatitis C in the difficult-to-treat patient[J].Liver Int, 2007, 27 (10) :1297-1310.

[3]Hughes CA, Shafran SD.Chronic hepatitis C virus management:2000-2005 update[J].Ann Pharmacother, 2006, 40 (1) :74-82.

[4]Bartosch B, Dubuisson J, Cosset FL.Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes[J].J Exp Med, 2003, 197 (5) :633-642.

[5]Lindenbach BD, Evans MJ, Syder AJ, et al.Complete replication of hepatitis C virus in cell culture[J].Science, 2005, 309 (5734) :623-626.

[6]Wakita T, Pietschmann T, Kato T, et al.Production of infectious hepatitis C virus in tissue culture from a cloned viral genome[J].Nat Med, 2005, 11 (7) :791-796.

[7]Pileri P, Uematsu Y, Campagnoli S, et al.Binding of hepatitis C virus to CD81[J].Science, 1998, 282 (5390) :938-941.

[8]Grove J, Huby T, Stamataki Z, et al.Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity[J].J Virol, 2007, 81 (7) :3162-3169.

[9]Kapadia SB, Barth H, Baumert T, et al.Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I[J].J Virol, 2007, 81 (1) :374-383.

[10]Evans MJ, von HT, Tscherne DM, et al.Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry[J].Nature, 2007, 446 (7137) :801-805.

[11]Liu S, Yang W, Shen L, et al.Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection[J].J Virol, 2009, 83 (4) :2011-2014.

[12]Timpe JM, Stamataki Z, Jennings A, et al.Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies[J].Hepatology, 2008, 47 (1) :17-24.

[13]Pietschmann T.Virology:Final entry key for hepatitis C[J].Nature, 2009, 457 (7231) :797-798.

[14]Griffin SD, Beales LP, Clarke DS, et al.The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine[J].FEBS Lett, 2003, 535 (1-3) :34-38.

[15]Pietschmann T, Kaul A, Koutsoudakis G, et al.Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras[J].Proc Natl Acad Sci U S A, 2006, 103 (19) :7408-7413.

[16]Noppornpanth S, Lien TX, Poovorawan Y, et al.Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus[J].J Virol, 2006, 80 (15) :7569-7577.

[17]Gosert R, Egger D, Lohmann V, et al.Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons[J].J Virol, 2003, 77 (9) :5487-5492.

[18]Watashi K, Ishii N, Hijikata M, et al.Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase[J].Mol Cell, 2005, 19 (1) :111-122.

[19]Li K, Foy E, Ferreon JC, et al.Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF[J].Proc Natl Acad Sci U S A, 2005, 102 (8) :2992-2997.

[20]Meylan E, Curran J, Hofmann K, et al.Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus[J].Nature, 2005, 437 (7062) :1167-1172.

[21]Sarrazin C, Rouzier R, Wagner F, et al.SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders[J].Gastroenterology, 2007, 132 (4) :1270-1278.

[22]Inchauspe G, Feinstone S.Development of a hepatitis C virus vaccine[J].Clin Liver Dis, 2003, 7 (1) :243-259.

[23]Chapel C, Garcia C, Roingeard P, et al.Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles[J].J Gen Virol, 2006, 87 (Pt 4) :861-871.

[24]Inoue K, Umehara T, Ruegg UT, et al.Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo[J].Hepatology, 2007, 45 (4) :921-928.

[25]Whitby K, Taylor D, Patel D, et al.Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV:implications for the treatment of hepatitis C[J].Antivir Chem Chemother, 2004, 15 (3) :141-151.

施引文献

资源附件(0)

访问统计